MB comment: Chickenpox vaccine failure (varicella) gets a frank review in this new study. ‘Conclusions: Literature to-date indicates a relatively high rate of primary vaccine failure.’ ‘Antibody titers fall during the first year post-vaccination.’
Of course, these are vaccine freaks – so vaccine failure is automatically transmuted into success and becomes the justification for more doses of an ineffective vaccine. ‘the second dose should be given soon after the first, since antibody titers are correlated with protection.’
Got that? Get more doses of this useless vaccine as soon as possible because it doesn’t work.
How about adverse reactions? According to the Merck Varivax (varicella vaccine) package insert 4% in the original clinical trial developed a ‘Varicella – like rash (generalized)’ In other words, 4% got chickenpox.
And in post marketing use (real world) these adverse events have been reported ‘Encephalitis; cerebrovascular accident; transverse myelitis; Guillain-Barré syndrome; Bell’s palsy; ataxia; non-febrile seizures; aseptic meningitis.’ These are severe neurological reactions that can cause lifetime disability and/or death.
And lest you forget, Merck’s Varivax is a certified blockbuster pharmaceutical product, with 2012 global sales of $1.34 billion! More doses equals more profits!
So rush on down to your doctor’s office, corner drug store or public school nurse’s office and get multiple doses of this failed and dangerous vaccine so you can be protected and so Merck can rack up even higher Varivax sales growth in 2013 – which (after all) is what the chickenpox vaccine is all about!
******************************************************************************
Primary Versus Secondary Failure Following Varicella Vaccination: Implications for Interval between Two Doses
Abstract
Background: Two-dose varicella vaccination is recommended for optimal control of varicella in populations with high (>90%) one-dose coverage. Optimal timing of the second dose may depend on whether breakthrough varicella results from primary vaccine failure (no protective immunity after vaccination) or secondary vaccine failure (waning protective immunity).
Methods: Published literature (1995-2012) on vaccine failure following varicella vaccination cited in PubMed and other online sources was reviewed.
Results: Nineteen publications detailed 21 varicella outbreaks with breakthrough varicella rates ranging from 0% to 42%; the publications showed no consistent trend between breakthrough varicella rate and time since vaccination.
Conclusions: Literature to-date indicates a relatively high rate of primary vaccine failure and limited evidence of secondary vaccine failure amongst one-dose varicella vaccine recipients, suggesting that a short interval between two doses might be preferable in countries considering implementation of universal varicella vaccination to reduce breakthrough varicella. However, any potential disruption to well-established vaccination schedules should be considered.
In 1986 a vaccine industry shill made the prediction that a chicken pox vaccine would save 264 million dollars, because parents staying home from work to care for a child with chicken pox cost 400 million dollars. He said this would only be the case if one dose of vaccine provided life-long immunity, if chicken pox did not shift to older people, and if use of the vaccine did not increase or worsen shingles. It’s almost as if he knew what was going to happen. Preblud SR. Varicella: complications and costs. Pediatrics. 1986 Oct;78(4 Pt 2):728-35.